Janssen Vaccine (Ad26.COV2.S)

Status
To Patients
Condition
COVID-19
Intervention Type
Intramuscular (IM) Injection
Funder Type
Industry

Drug Details

Ad26.COV2.S is a COVID-19 vaccine based on a human replication-incompetent Ad26 vector, constructed to encode the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) virus spike (S) protein.

More Information

On February 27, 2021, the U.S. Food and Drug Administration issued an emergency use authorization (EUA) for the third vaccine for the prevention of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The EUA allows the Janssen COVID-19 Vaccine to be distributed in the U.S. for use in individuals 18 years of age and older.

Janssen COVID-19 Vaccine




 

footer_txt_bblBook a PFF Ambassador for your event.   Call 844.TalkPFF >